Author: Lee, Yong-ho; Kim, Jae Hyeon; Kim, So Ra; Jin, Heung Yong; Rhee, Eun-Jung; Cho, Young Min; Lee, Byung-Wan
Title: Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness Document date: 2016_11_8
ID: 4fwp1dnl_22
Snippet: For multivariate linear regression analyses, a change in CAP value following lobeglitazone treatment was used as a dependent factor, and the baseline variables were adjusted (Model 1). Changes in CAP values were independently associated with baseline CAP and LSM values, white blood cell (WBC) counts, ALT, and γGTP levels, and the use of metformin. Using such analyses, we would expect CAP decrements after lobeglitazone treatment in subjects with .....
Document: For multivariate linear regression analyses, a change in CAP value following lobeglitazone treatment was used as a dependent factor, and the baseline variables were adjusted (Model 1). Changes in CAP values were independently associated with baseline CAP and LSM values, white blood cell (WBC) counts, ALT, and γGTP levels, and the use of metformin. Using such analyses, we would expect CAP decrements after lobeglitazone treatment in subjects with higher baseline levels of CAP, WBC, and ALT, as well as metformin users; on the other hand, we would expect non-responsiveness to lobeglitazone in those who have higher baseline LSM values and γGTP levels. Model 2, which included changes in clinico-laboratory parameters, showed that CAP value changes were only independently associated with alterations in ALT levels after 24
Search related documents:
Co phrase search for related documents- ALT level and blood cell: 1, 2, 3, 4, 5, 6, 7
- baseline level and blood cell: 1, 2, 3
- blood cell and CAP value: 1, 2
- CAP value and clinico laboratory: 1
Co phrase search for related documents, hyperlinks ordered by date